Solidus Investment
VC Fund
Seoul, South Korea
Solidus Investment is a VC fund in Seoul focused on Biotechnology and Health Care. Solidus Investment Co., Ltd is a venture capital founded in June 2011 by CHA Medical Center Group. They discover and invest companies with growth potential in Bio/agricukural and marine products/ green energy / IT industry, etc.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Solidus Investment invests in
Stages Solidus Investment invests in
Countries Solidus Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $1.8M–$17M
- Series C
- $15M–$24M
- Venture - Series Unknown
- $5.3M–$9.9M
Investment Focus
Industry
- Biotechnology 18 (40%)
- Health Care 17 (38%)
- Pharmaceutical 7 (16%)
- Medical 6 (13%)
- Information Technology 6 (13%)
Stage
- Venture - Series Unknown 11 (24%)
- Series B 10 (22%)
- Series C 8 (18%)
- Series A 7 (16%)
- Funding Round 6 (13%)
Country
- South Korea 39 (87%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kim Jeong
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $14M / Series B / Jun 16, 2026 | ||
| PEOPLE AND TECHNOLOGY provides DX-based AI solutions on INDOOR GEOLOCATION AND SMART SENSING through its INDOORPLUS+ IoT, Location Based System (LBS) and Real Time Location System (RTLS) platform in the fields of healthcare, manufacturing, defense, smart cities, and the public sector.More than 100 corporate customers in various business sectorssuch as healthcare, banking, manufacturing, retail, energy and public services have already chosen PEOPLE AND TECHNOLOGY to deploy industry grade solutions for employee safety, asset tracking & monitoring, security & access control, flow management and process efficiency. They have gained improvements in productivity and process efficiency while reducing their corporate risks and optimizing their procurement. Since its foundation in 2013, PEOPLE AND TECHNOLOGY has become a leading provider in South Korea and is expanding overseas. | $9.9M / Venture - Series Unknown / Apr 07, 2026 | ||
| AITRICS delivers AI-powered medical software designed to support clinicians in detecting and preventing critical patient deterioration. The company’s core product, AITRICS‑VC (VitalCare), continuously monitors data from electronic medical records (EMRs), including vital signs, lab tests, consciousness levels, and other relevant clinicalmeasurements to predict adverse events such as sepsis, cardiac arrest, unexpected ICU transfers, or mortality several hours before they occur.AITRICS-VC operates in real time, delivering risk scores and alerts to clinicians to enable earlier intervention and better resource allocation in hospital settings. The platform has been certified by the relevant regulatory authority in its home country and is classified as an “innovative medical device,” reflecting regulatory recognition of its predictive-analytics capabilities. In addition to monitoring and prediction, AITRICS engages in ongoing clinical validation and research; it publishes studies in peer-reviewed journals and presents its work in international AI conferences, indicating a commitment to evidence-based development and transparency in performance. | $23.8M / Series C / Dec 01, 2025 | ||
Cureverse
|
Cureverse operates a pharmaceutical research and development company for the treatment of encephalopathy and oncology diseases. The company focuses on creating remedies for challenging brain conditions like dementia, thereby assisting healthcare professionals in enhancing human well-being and overall quality of life. | $17.1M / Series B / Jan 17, 2025 | |
| GB SOFT Co.,Ltd. is the developer of non-contact measurement solutions for bio-signals such as pulse, blood pressure, oxygen saturation, and HRV(Heart Rate Variability). These bio-signals can be used for basic health status checks in daily life and at medical sites. Analyzing these signals can calculate fatigue, drowsiness, stress index, and bloodsugar. These indices can be widely used in the automotive, transportation, construction, manufacturing, and well-being industries. The measurement process takes less than 10 seconds and has the highest accuracy worldwide. GB SOFT's goal is to make a world where everyone can experience a convenient daily life with non-contact bio-signal measurement systems. | $5.5M / Series B / Jan 08, 2025 | ||
| Dr.Diary offers diabetes management application services. | $5.3M / Venture - Series Unknown / Jan 08, 2025 | ||
| Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $17.6M / Dec 23, 2024 | ||
| Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $17.7M / Series C / Dec 23, 2024 | ||
| Mepseng is the eveloper of micro-engineered physiological systems designed to create human model-centered drugs. The company's systems carry out fundamental biological research in an environment equipped with an organ-level function of connected human tissues instead of in a traditional in-vitro experimental model using 2D cell culture,enabling researchers to further verify in a physiologically relevant environment to validate the discovery of new biological mechanisms. | $14.9M / Series C / Nov 19, 2024 | ||
| Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role.In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF)and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development. | $16.6M / Series C / Nov 11, 2024 | ||
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Solidus Investment invest in?
Solidus Investment invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Venture - Series Unknown and Series B stage. Most of the 45 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Solidus Investment invest in?
Solidus Investment typically joins rounds of $1.8M–$17M at Series B, $15M–$24M at Series C and $5.3M–$9.9M at Venture - Series Unknown. These are whole funding-round sizes, not Solidus Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Solidus Investment took part in.
How do I contact Solidus Investment?
Public channels for Solidus Investment include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Solidus Investment?
The team at Solidus Investment includes Kim Jeong (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
